COVID-19 Vaccine: Inactivated by Sinovac, Instituto Butatan

distribution (started in December 2020):
Albania, Algeria, Armenia, Azerbaijan, Bangladesh, Benin, Bosnia and Herzegovina, Botswana, Brazil, Cambodia, Chile, China, Colombia, Djibouti, Dominican Republic, Ecuador, Egypt, El Salvador, Ethiopia, Georgia, Guinea, Hong Kong, Indonesia, Laos, Libya, Malaysia, Mexico, North Macedonia, Northern Cyprus, Oman, Pakistan, Palestine, Paraguay, Philippines, Rwanda, Singapore, Somalia, Sudan, Syria, Tajikistan, Thailand, Timor, Tunisia, Turkey, Uganda, Ukraine, Uruguay, Uzbekistan, Venezuela, Yemen, Zimbabwe

Distribution updates

Feb 08	Sinovac announced that China's NMPA has granted a conditional marketing authorization for CoronaVac (by sinovacbio.com)
Feb 03	Sinovac has officially filed for conditional market authorization for CoronaVac with China's NMPA (by sinovacbio.com)
Jan 20	Chile's health regulator approved the emergency roll-out of Sinovac's COVID-19 vaccine (by reuters.com)
Jan 17	Anvisa approved Sinovac's COVID-19 vaccine for emergency use in Brazil (by gov.br)
Jan 13	Turkey's Medicines and Medical Devices Agency granted emergency use authorization to Sinovac's vaccine (by reuters.com)
Jan 11	Indonesia gave Sinovac's vaccine its first emergency use approval outside China launching nationwide inoculations (by reuters.com)
Aug 11	Sinovac is hopeful to start producing the vaccine in January 2021 clinical trials are successful (by jakartaglobe.id)

Human Testing updates (clinical trials)

PHASE 1-2 (Jiangsu)

started April 13 2020

with 744 healthy volunteers aged 18-59

trial location: Xuzhou, Jiangsu, China

» clinical trial details

PHASE 1-2 (Hebei)

started May 20 2020

with 422 healthy volunteers aged 60+

trial location: Renqiu, Hebei, China

» clinical trial details

PHASE 1-2 (Hebei children)

started September 28 2020

with 552 healthy children aged 3-17

trial location: Shijiazhuang, Hebei, China

» clinical trial details

PHASE 3 (Brazil)

started July 2 2020

with 8870 healthy volunteers aged 18+

trial location: Brazil

» clinical trial details

PHASE 3 (Indonesia)

started August 10 2020

with 1620 healthy volunteers aged 18-59

trial location: Indonesia

» clinical trial details

PHASE 3 (Turkey)

started September 14 2020

with 13000 healthy volunteers aged 18-59

trial location: Turkey

» clinical trial details

PHASE 3 (China)

started October 31 2020

with 1040 healthy volunteers aged 18+

trial location: Yancheng, Jiangsu, China

» clinical trial details

PHASE 3 (Chile)

started November 27 2020

with 2300 healthy volunteers aged 18+

trial location: Santiago, Chile

» clinical trial details

PHASE 4

started February 2021

with 1200 healthy volunteers aged 18+

trial location: Rio De Janeiro, Brazil

» clinical trial details

PHASE 4

started February 17 2021

with 30000 healthy volunteers aged 18+

trial location: Sao Paulo, Brazil

» clinical trial details

Jan 12	Sinovac's vaccine suffered a setback after a late-stage trial in Brazil showed that their vaccine is 50% effective (by wsj.com)
Dec 23	Sinovac has delayed the announcement of results from late-stage trials of its vaccine to January (by wsj.com)
Nov 24	Brazil gathered enough infection data from a late-stage Sinovac's vaccine trial expecting to have results on its efficiency in early December (by reuters.com)
Nov 17	CoronaVac triggered a quick immune response but level of antibodies produced was lower than those who recovered from COVID-19 (by reuters.com)
Nov 11	Brazilian health authority authorised the restart Wednesday of clinical trials of China's Sinovac vaccine (by wsj.com)
Nov 10	Brazil health regulator has suspended Sinovac's vaccine clinical trials due to a severe adverse event (by wsj.com)
Sep 23	Sinovac's vaccine was approved by NMPA for clinical trial in adolescents and children (by businesswire.com)
Sep 22	Sinovac's Phase 3 clinical trial seeks to test efficacy and safety of the vaccine Turkey (by sinovac.com)
Sep 16	Sinovac's final Phase 3 trials started in Turkey where up to 1200 health workers will be administered with the vaccine (by dailysabah.com)
Sep 09	Sinovac's Phase 3 clinical trials taking place in Brazil have shown promising results (by reuters.com)
Sep 07	Sinovac's vaccine candidate appeared to be safe for older people according to preliminary results from an early to mid-stage trial (by reuters.com)
Aug 28	Sinovac's CoronaVac was approved for emergency use in China to vaccinate high risk groups (by reuters.com)
Aug 10	Sinovac launched Phase 3 clinical trials of its vaccine involving 1620 patients in Indonesia (by reuters.com)
Jul 28	Instituto Butatan and Sao Paulo Gov. will start Phase 3 clinical trials in four new research centers (by sp.gov.br)
Jul 21	First volunteers have been dosed with Sinovac's vaccine at Uni of Sao Paulo's hospital in Brazil (by sp.gov.br)
Jul 06	Sinovac's vaccine collaboration with Butatan received approval from Brazil regulator for Phase 3 (by businesswire.com)
Jun 11	Sinovac signed a clinical development agreement with Instituto Butatan to advance to Phase 3 (by sinovac.com)
Apr 17	Sinovac has commenced Phase 1 clinical trial for its vaccine enrolling healthy volunteers (by businesswire.com)
Apr 14	Sinovac has obtained approval to conduct a human clinical trial on a vaccine candidate (by businesswire.com)
Jan 07	Sinovac's vaccine has shown to be 78% effective against COVID-19 in Brazilian late-stage trials (by wsj.com)

Animal Testing updates (pre-clinical trials)

start date: March 2020

May 06	Sinovac's vaccine dosis provided partial or complete protection in macaques (by sciencemag.org)
Apr 24	Sinovac published the results of testing their vaccine on animals (by channelnewsasia.com)
Apr 19	A Sinovac vaccine candidate successfully gives complete protection in non-human primates (by biorxiv.org)

early development updates

currently no early development info

funding:

Advantech Capital + Vivo Capital $7.5m each + Sino Biopharmaceutical Limited US $500M

Dec 06	Sinovac announced that Sinovac Life Sciences Co.Ltd. has secured US$500M in funding for further devolopment of the vaccine (by businesswire.com)
May 25	Advantech Capital and Vivo Capital have invested $7.5m each for Sinovac's vaccine development (by pharmaceutical-technology.com)

Inactivated + alum CoronaVac